SynthesisFrontiers in medicine2021
Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease.
Synthesis in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Advanced hydrogel-based drug delivery systems for psoriasis management: From material design to multi-target therapies.International journal of pharmaceutics: X · 2026Review
- The role of phototherapy in reducing the risk of psoriatic arthritis among psoriasis patients in the era of biologics.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- PDE4 inhibitors in psoriasis therapy: current insights and future directions.Inflammopharmacology · 2025Review
- Enhanced Topical Delivery of Methotrexate via Transferosome-Loaded Microneedle Array Patch: Formulation, Optimization, and In Vitro-In Vivo Assessment.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring the polarization of M1 and M2 macrophages in the context of skin diseases.Molecular biology reports · 2024Review
- Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.Frontiers in immunology · 2024Article
- A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders.JAAD case reports · 2023Article
- Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques.Scientific reports · 2023Article
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.Frontiers in medicine · 2022Review
- Role of Cyclosporine (CsA) in Immuno-dermatological Conditions.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.